APA (7th ed.) Citation

Ebel, F., Deterding, K., Port, K., Schlevogt, B., Manns, M. P., Maasoumy, B., . . . Wedemeyer, H. (2020). Letter: A 5‐year long‐term follow‐up study after DAA treatment confirms a reduced HCC risk in a central European cohort of HCV patients with liver cirrhosis. Alimentary Pharmacology & Therapeutics, 51(1), 194. https://doi.org/10.1111/apt.15597

Chicago Style (17th ed.) Citation

Ebel, Friederike, Katja Deterding, Kerstin Port, Bernhard Schlevogt, Michael P. Manns, Benjamin Maasoumy, Markus Cornberg, and Heiner Wedemeyer. "Letter: A 5‐year Long‐term Follow‐up Study After DAA Treatment Confirms a Reduced HCC Risk in a Central European Cohort of HCV Patients with Liver Cirrhosis." Alimentary Pharmacology & Therapeutics 51, no. 1 (2020): 194. https://doi.org/10.1111/apt.15597.

MLA (9th ed.) Citation

Ebel, Friederike, et al. "Letter: A 5‐year Long‐term Follow‐up Study After DAA Treatment Confirms a Reduced HCC Risk in a Central European Cohort of HCV Patients with Liver Cirrhosis." Alimentary Pharmacology & Therapeutics, vol. 51, no. 1, 2020, p. 194, https://doi.org/10.1111/apt.15597.